BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY

File: 120396_sep96_decls73_0005.txt
Page: 0005
Total Pages: 10

Subject: BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY                  

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY                                                  

Document Number:          1

Folder SEQ  #:         66







                                 VACCINE ACQUISITION PROGRAM TALKING POINTS
                                      I

                VACCINE PRODUCTION FACILITY
                       - SITES REVIEW AND COST ASSESSMENTS COMPLETED
                             5 SITES - PINE BLUFF BEST IN TERMS OF COST TO BUILD AND RUN

                       -35% CONCEPT AND DESIGN COMPLETED .... REVIEW IN PROGRESS AND CLEAN-UP
                             OF DETAILS OCCURRING NOW.
                             -PROBLEMS AREAS
                                   NO ACCESS TO CLASSIFIED OR PROPRIETARY DATA
                                   NO VACCINE POLICY AVAILABLE SO NO BASIS FOR PRODUCTION
                                         REQU         S
                                   LIMITED PRODUCTION PROCESS DATA AVAILABLE


                             - UNIQUE ONE OF A KIND FACILITY ... STATE OF THE ART: 475,000 SF
                                   3 BUILDINGS; ANIMAL FACILITY, PRODUCTION /WAREHOUSING
                                   AND UTILITY.


                             - MINIMUM OF 17 DIFFERENT PRODUCTS ANTICIPATED; FLEXIBILITY
                                   IN PRODUCTION

                       -PBD UPDATE...-SIMMONS INDICATED PERRY WAS GOING TO SIGN LAST
                       WEEK ... HAS 378 BEEN SIGNED?? IF SO WHERE FROM HERE?? ... WHY DO EA?


                             CONGRESSIONAL LANGUAGE PROHIBITS EXI'ENDITURE OF FY94 MCA
                             FUNDS UNTIL CONSTRUCTION ISSUE RESOLVED

                       -EA ON VACCINE ACQUISITION WILL BE COMPLETED 17 JANUARY. EXECUTTVE
                       SUMMARY AVAILABLE 7 JANUARY.


                             -ASSUMPTIONS FOR EA WILL BE AS CLOSE TO IDENTICAL AS POSSIBLE TO
                             THOSE USED IN CONCEPT AND DESIGN STUDY


                             -SIGNIFICANT ISSUES WHICH ARE DIFFICULT TO ASSESS IN EA
                                   -INDEMNIFICATION
CTORS
                                   - FDA REGULATIONS
                                         LICENSER VS IND
                                          BULK PRODUCT STORAGE MUST BEAT PRODUCTION SITE
                                   - PROPRIETARY INFORMATION ACCESS


                       VACCINE ACQUISITION

                             PBD 109 HAS BEEN SIGNED
                                   MOVED SS FOR VACCINE PROCURE       AND NMD 6.3B/6A
                                   R&D TO JPO-BD


                             WE CAN NOW START TO ACQUIRE BASED ON NEW POLICY SIGNED 26
                             NOVEMBER 93
                                   @CIPAT-E RECEIVING CINC REQUIREMENTS BASE ON
                                         T/ORDER OF BATTLE AND WEAPONS AVAILABLE IN APRIL 94

Document 10 f:/Week-36/BX003203/BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY/biological defense vaccine production facility:11259610130813
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY
Folder Seq # = 66
Subject = BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 25-NOV-1996